AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03474029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin daily for 16 weeks
Description: Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing > 50 kg. For persons weighing \< 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg.
Study NCT00385788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 800 mg/m\^2 IV over 30 minutes on Day -7 (1 day)
Study NCT00385788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 33 mg/m\^2 IV over 30 minutes Day -5 to Day -2 (4 days)
Study NCT00385788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
Study NCT00385788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: 2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant.
Study NCT00385788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Infusion
Description: Infusion of stem cells on Day 0.
Study NCT00385788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
Study NCT00385788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
Study NCT00385788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
Study NCT02283190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.
Study NCT01629394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
Study NCT01629394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Single dose of sugammadex 2 mg/kg ( ideal body weight )
Study NCT01629394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
Study NCT01629394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Single dose of neostigmine 50 μg/kg ( ideal body weight )
Study NCT01629394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)\]
Study NCT01629394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Single dose of neostigmine 50μg/kg ( ideal body weight )
Study NCT01726764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT04573972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Incentive
Description: Receiving half the monetary incentive conditional on meeting a step goal and half the monetary incentive conditional on walking together
Study NCT00958802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Description: PRP was extracted from total blood and TGF-b1 was used as indicator
Study NCT00958802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chondrocyte culture with FBS medium
Description: Microtia chondrocyte culture with FBS medium only
Study NCT04187209 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Use of the Atalante exoskeleton
Description: A session includes a stand-up, walks over a distance of 10 meters, exercises with or without the assistance of the exoskeleton, U-turns and a sitting.
Study NCT03092635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC
Description: OPC is a derivative of grape seed extract
Study NCT04372797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic test
Description: A battery of oculomotor tests
Study NCT03259932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no physical activity
Description: no physical activity
Study NCT03259932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Rehabilitation program will start 4 weeks after discharge from acute care (S4), for a duration of 8 weeks (3 sessions / week). Physical training will include aerobic exercises 30-60 minutes at 50-80% of HRmax, associated with muscle building exercises in circuit training (20 min), and balance and flexibility exercises.
Study NCT04456348 — intervention group
Intervention type: OTHER
Intervention: there is no intervention
Description: There is no intervention
Study NCT04283825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological and physical rehabilitation based humanistic care
Description: This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.
Study NCT03588845 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment Protocol
Description: Protocol treatment sites will be expected to see the patient within a pre-specified window of time. The doctors at that site will apply the treatment algorithm and will make decisions about response to treatment based on the algorithm and on specific patient answers to questionnaires. The treatment protocol will only be made available to IRBs, not to any site personnel before randomization. This was derived from a survey of rheumatologists in many countries and gastroenterologists, mostly in North America, who were asked multiple questions about how they would treat and follow up patients with suspected SIBO. Successful treatment is a response on GSS of no diarrhea plus a total GSS of \< 5.
Study NCT03588845 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Physicians randomly assigned to standard of care will also be informed of their patients who met eligibility criteria. They will not be aware of the detailed treatment protocol but will be informed of which medications are in the protocol eg antibiotics, prokinetics etc. They will be free to contact the patients at their convenience and to treat them in any way they deem suitable, preferably using these medications but at doses and frequencies according to their own wishes.
Study NCT04372797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic test
Description: A battery of oculomotor tests
Study NCT01183780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Study NCT01183780 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Study NCT03384433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: exosome
Description: allogenic mesenchymal stem cells derived exosome enriched by miR-124
Study NCT01309217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics Intervention
Description: At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals.
Study NCT04573972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Incentive
Description: Receiving the full monetary incentive conditional on meeting a step goal and not conditional on walking together
Study NCT00378092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral risperidone
Description: Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
Study NCT01183780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan
Description: 180 milligrams/square meter (mg/m\^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Study NCT01183780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 milligrams/square meter (mg/m\^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Study NCT01183780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folinic Acid
Description: 400 mg/m\^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Study NCT01183780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400 mg/m\^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Study NCT01183780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: 400 mg/m\^2 bolus immediately followed by 2400 mg/m\^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Study NCT01183780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m\^2 bolus immediately followed by 2400 mg/m\^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Study NCT01669148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tomosynthesis
Description: The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
Study NCT01669148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: conventional (2D) imaging (standard mammography)
Study NCT03329742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein diet
Description: Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 10% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
Study NCT03329742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control protein diet
Description: Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 20% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
Study NCT00702806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Intra-abdominal injection of Org 36286
Study NCT00702806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puregon®
Description: Subcutaneous Puregon® 150 IU
Study NCT00702806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Puregon®
Description: Subcutaneous Puregon® 150 IU
Study NCT00702806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orgalutran®
Description: Subcutaneous Orgalutran® 0.25 mg
Study NCT00702806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orgalutran®
Description: Subcutaneous Orgalutran® 0.25 mg
Study NCT00702806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnyl®
Description: Subcutaneous Pregnyl® 10,000 IU
Study NCT00702806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnyl®
Description: Subcutaneous Pregnyl® 10,000 IU
Study NCT02674646 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation as indicated by the cancer diagnosis
Study NCT02674646 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Radiotherapy
Description: Radiation as indicated by the cancer diagnosis
Study NCT02674646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle Acupuncture
Description: Needle Acupuncture according to Traditional Chinese Medicine (TCM)
Study NCT02674646 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Needle Acupuncture
Description: Needle Acupuncture according to Traditional Chinese Medicine (TCM)
Study NCT01700400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT01700400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT01700400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01700400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT03298919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Video Games
Description: 12 weeks laboratory based exercise videogames
Study NCT03298919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Stationary bike and/or treadmill walking for 12 weeks
Study NCT03298919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise videogames
Description: videogame console and active videogames
Study NCT03298919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Standard Exercise
Description: Personalized physical activity promotion materials
Study NCT00155558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Leucovorin
Study NCT01595854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: medium dose dabigatran
Study NCT01595854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: high dose ticagrelor
Study NCT01595854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: high dose ticagrelor
Study NCT01595854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: low dose dabigatran
Study NCT03610958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epitomee Device
Description: A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.
Study NCT01309217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
Study NCT02551679 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACP-01
Description: Injection into lower extremity
Study NCT02551679 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection into lower extremity
Study NCT01521078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Your Drinking University version
Description: The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
Study NCT04352582 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey
Study NCT02959658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl fumarate
Study NCT02959658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Manufactured to mimic Dimethyl Fumarate capsules
Study NCT01312337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvage iressa
Description: Iressa 250mg per day until progression
Study NCT02523391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Capsule
Study NCT02523391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Tablet
Study NCT01295086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 42, 51 or 60 mg/m² day 1 every 3. week
Study NCT01295086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m² day 1 every 3. week
Study NCT01295086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250 mg/² continuously
Study NCT01295086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
Study NCT00186823 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Miltenyi Biotec CliniMACS
Description: A stem cell selection device.
Study NCT00186823 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
Study NCT00186823 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TBI, systemic chemotherapy and antibodies as follows:
Description: Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
Study NCT01997684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonic Stenting with Elective Surgery
Description: After preparation of the distal colon with an enema, the colonoscope will be introduced up to the site of the obstruction. The colonic stent will be placed along a guide wire through the lesion under radiologic or endoscopic guidance. A colonic stent will be chosen which was at least 3 cm longer than the lesion (1.5 cm at either end). When the colonic stent did not cover the entire length of the lesion, a second overlapping stent will be placed.~If the colonic stenting failed (technical failure) or symptoms of colonic obstruction did not resolve within 3 days (clinical failure), patients were indicated for emergency surgery.~Candidates for elective surgery were preferably operated on 5-14 days after colonic stenting, and no later than 4 weeks.~Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
Study NCT01997684 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency Surgery
Description: Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
Study NCT04659551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles
Study NCT04659551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles
Study NCT04659551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin 3.75 mg i.m. every 4 weeks until surgery
Study NCT00378092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Long-Acting Injection (RLAI)
Description: RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.